Lambisia Arnold W, Katama Esther N, Moraa Edidah, Mwita John M, Gallagher Katherine, Mutunga Martin, Nyale Emily, Omungala Joan, Mwanga Mike, Murunga Nickson, Nyiro Joyce, Nyagwange James, Sande Charles, Bejon Philip, Githinji George, Dellicour Simon, Phan My V T, Cotten Matthew, Ochola-Oyier L Isabella, Holmes Edward C, Agoti Charles N
Kenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Department of Infectious Diseases Epidemiology, London, School of Hygiene and Tropical Medicine , Keppel Street, London, UK.
BMC Glob Public Health. 2025 Sep 9;3(1):80. doi: 10.1186/s44263-025-00201-6.
Between November 2023 and March 2024, coastal Kenya experienced another wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections detected through our continued genomic surveillance. Herein, we report the clinical and genomic epidemiology of SARS-CoV-2 infections from 179 individuals (a total of 185 positive samples) residing in the Kilifi Health and Demographic Surveillance System (KHDSS) area (~ 900 km).
We analyzed genetic, clinical, and epidemiological data from SARS-CoV-2 positive cases across pediatric inpatient, health facility outpatient, and homestead community surveillance platforms. Phylogenetic analyses were performed using maximum-likelihood and Bayesian frameworks. Temporal trends were summarized, comparisons conducted using Kruskal-Wallis and Wilcoxon tests, and associations examined using univariate and multivariable logistic regression models.
Sixteen SARS-CoV-2 lineages within 3 subvariants [XBB.2.3-like (58.4%), JN.1-like (40.5%), and XBB.1-like (1.1%)] were identified. The symptomatic infection rate was estimated at 16.0% (95% CI, 11.1-23.9%) based on community testing regardless of symptom status and did not differ across the subvariants (p = 0.13). The most common infection symptoms in community cases were cough (49.2%), fever (27.0%), sore throat (7.3%), headache (6.9%), and difficulty in breathing (5.5%). One case succumbed to the infection. Genomic analysis of the virus from serial positive samples confirmed repeat infections among 5 participants under follow-up (median interval 21 days, range 16-95 days); in 4 participants, the same virus lineage was responsible in both episodes, whereas 1 participant had a different lineage in the second compared with the first episode. Phylogenetic analysis including > 18,000 contemporaneous global sequences provided evidence for at least 38 independent virus introduction events into the study area (KHDSS) during the wave, the majority likely originating in North America and Europe.
Our study highlights that coastal Kenya, like most other localities, continues to face new SARS-CoV-2 infection waves characterized by circulation of new variants, multiple lineage importations, and reinfections. Locally, the virus may circulate unrecognized, as most infections are asymptomatic in part due to high population immunity after several waves of infection. Our findings highlight the need for sustained SARS-CoV-2 surveillance to inform appropriate public health responses, such as scheduled vaccination for populations at risk of severe infection.
2023年11月至2024年3月期间,肯尼亚沿海地区通过我们持续的基因组监测,经历了另一波严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染。在此,我们报告了居住在基利菲健康与人口监测系统(KHDSS)地区(约900公里)的179名个体(共185份阳性样本)的SARS-CoV-2感染的临床和基因组流行病学情况。
我们分析了来自儿科住院患者、医疗机构门诊患者以及家庭社区监测平台的SARS-CoV-2阳性病例的基因、临床和流行病学数据。使用最大似然法和贝叶斯框架进行系统发育分析。总结了时间趋势,使用Kruskal-Wallis检验和Wilcoxon检验进行比较,并使用单变量和多变量逻辑回归模型检验关联。
在3个亚变体中鉴定出16种SARS-CoV-2谱系[XBB.2.3样(58.4%)、JN.1样(40.5%)和XBB.1样(1.1%)]。基于社区检测,无论症状状态如何,有症状感染率估计为16.0%(95%CI,11.1-23.9%),且在各亚变体之间无差异(p=0.13)。社区病例中最常见的感染症状为咳嗽(49.2%)、发热(27.0%)、咽痛(7.3%)、头痛(6.9%)和呼吸困难(�.5%)。有1例患者死于感染。对系列阳性样本中的病毒进行基因组分析,证实5名随访参与者中存在重复感染(中位间隔21天,范围16-95天);在4名参与者中,两次发作均由同一病毒谱系引起,而1名参与者在第二次发作时与第一次发作的病毒谱系不同。包括超过18,000条同期全球序列的系统发育分析为该波疫情期间至少38次独立的病毒引入事件进入研究区域(KHDSS)提供了证据,其中大多数可能起源于北美和欧洲。
我们的研究强调,肯尼亚沿海地区与大多数其他地区一样,继续面临新的SARS-CoV-2感染浪潮,其特征为新变体的传播、多种谱系的输入和再感染。在当地,该病毒可能未被识别地传播,因为大多数感染无症状,部分原因是经过几波感染后人群具有较高的免疫力。我们的研究结果强调需要持续进行SARS-CoV-2监测,以为适当的公共卫生应对措施提供信息,例如为有严重感染风险的人群安排疫苗接种。